On A Roll With Otezla: Can New Orals And Injectables Crack Psoriasis?
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
New drugs for psoriasis and psoriatic arthritis have been in the spotlight recently, with new approvals and full pivotal data releases at the recent American Academy of Dermatology meeting. But how the drugs can make inroads in a safety- and cost-cautious market that will soon feature biosimilars remains to be seen.